Description: aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.
Home Page: www.atyrpharma.com
LIFE Technical Analysis
3545 John Hopkins Court
San Diego,
CA
92121
United States
Phone:
858 731 8389
Officers
| Name | Title |
|---|---|
| Dr. Sanjay S. Shukla M.D., M.S. | Pres, CEO & Director |
| Ms. Jill M. Broadfoot | Chief Financial Officer |
| Ms. Nancy E. Denyes Krueger | Gen. Counsel & Corp. Sec. |
| Xiang-Lei Yang Ph.D. | Founder |
| Ms. Ashlee Dunston | Director of Investor Relations & Corp. Communications |
| Mr. Peter Villiger | VP of Corp. Devel. |
| Ms. Danielle Campbell | VP of Human Resource |
| Dr. Leslie Nangle Ph.D. | VP of Research |
| Dr. Ying J. Buechler Ph.D. | Exec. Director of Biologics Devel. & Manufacturing |
| Dr. Melissa A. Ashlock | Sr. Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8306 |
| Price-to-Sales TTM: | 37.7611 |
| IPO Date: | 2015-05-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 49 |